Cargando…

Stark differences in cancer epidemiological data between GLOBOCAN and GBD: Emphasis on oral cancer and wider implications

BACKGROUND: GLOBOCAN 2020 and Global Burden of Disease (GBD) 2019 are the two most established global online cancer databases. It is important to examine the differences between the two platforms, to attempt to explain these differences, and to appraise the quality of the data. There are stark diffe...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, K.M., Rimal, J., Zhang, P., Johnson, N.W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561675/
https://www.ncbi.nlm.nih.gov/pubmed/36247925
http://dx.doi.org/10.1016/j.eclinm.2022.101673
_version_ 1784807999808733184
author Fan, K.M.
Rimal, J.
Zhang, P.
Johnson, N.W.
author_facet Fan, K.M.
Rimal, J.
Zhang, P.
Johnson, N.W.
author_sort Fan, K.M.
collection PubMed
description BACKGROUND: GLOBOCAN 2020 and Global Burden of Disease (GBD) 2019 are the two most established global online cancer databases. It is important to examine the differences between the two platforms, to attempt to explain these differences, and to appraise the quality of the data. There are stark differences for lip and oral cancers (LOC) and we attempt to explain these by detailed analysis of ten countries at the extremes of differences. METHODS: Age-standardised incidence rates (ASIR) of LOC were obtained from GLOBOCAN 2020 and GBD 2019. Five countries with the greatest and smallest fold differences were selected. A systematic search of PubMed and Embase electronic databases was then performed to identify publications reporting the incidence of LOC in the selected countries between 2015 and 2022. Specifically, data sources of the articles were examined and evaluated. FINDINGS: For LOC, greatest differences were found in Papua New Guinea, Vietnam, China, Pakistan, and Indonesia (group A). In contrast, the United States of America (USA), Brazil, France, Germany, and India (group B) had the least differences between the two databases. INTERPRETATION: It is not surprising that when GLOBOCAN and GBD could not obtain high-quality or accessible LOC data from national or local cancer registries, as in group A, discrepancies would be seen between the two online databases. In contrast, where only minor differences were seen between GLOBOCAN and GBD, as in group B, presumptively due to those countries having well-established cancer registries and healthcare administrative systems, the literature is more consistent. Moreover, many studies have grouped lip and oral cavity with pharynx and categorised outputs as “oral and oropharyngeal cancer” or “oral cavity and pharynx cancer”. Those categorisations lacked subsite accuracy and failed to realise that oral cancer and oropharyngeal cancer have completely different etiological factors, pathogeneses, prognosis, and treatment outcomes. FUNDING: This research received no specific grant or funding from any funding agency in the public, commercial, or not-for-profit sectors, and the authors received no financial support for the research, authorship, and/or publication of this article.
format Online
Article
Text
id pubmed-9561675
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-95616752022-10-15 Stark differences in cancer epidemiological data between GLOBOCAN and GBD: Emphasis on oral cancer and wider implications Fan, K.M. Rimal, J. Zhang, P. Johnson, N.W. eClinicalMedicine Articles BACKGROUND: GLOBOCAN 2020 and Global Burden of Disease (GBD) 2019 are the two most established global online cancer databases. It is important to examine the differences between the two platforms, to attempt to explain these differences, and to appraise the quality of the data. There are stark differences for lip and oral cancers (LOC) and we attempt to explain these by detailed analysis of ten countries at the extremes of differences. METHODS: Age-standardised incidence rates (ASIR) of LOC were obtained from GLOBOCAN 2020 and GBD 2019. Five countries with the greatest and smallest fold differences were selected. A systematic search of PubMed and Embase electronic databases was then performed to identify publications reporting the incidence of LOC in the selected countries between 2015 and 2022. Specifically, data sources of the articles were examined and evaluated. FINDINGS: For LOC, greatest differences were found in Papua New Guinea, Vietnam, China, Pakistan, and Indonesia (group A). In contrast, the United States of America (USA), Brazil, France, Germany, and India (group B) had the least differences between the two databases. INTERPRETATION: It is not surprising that when GLOBOCAN and GBD could not obtain high-quality or accessible LOC data from national or local cancer registries, as in group A, discrepancies would be seen between the two online databases. In contrast, where only minor differences were seen between GLOBOCAN and GBD, as in group B, presumptively due to those countries having well-established cancer registries and healthcare administrative systems, the literature is more consistent. Moreover, many studies have grouped lip and oral cavity with pharynx and categorised outputs as “oral and oropharyngeal cancer” or “oral cavity and pharynx cancer”. Those categorisations lacked subsite accuracy and failed to realise that oral cancer and oropharyngeal cancer have completely different etiological factors, pathogeneses, prognosis, and treatment outcomes. FUNDING: This research received no specific grant or funding from any funding agency in the public, commercial, or not-for-profit sectors, and the authors received no financial support for the research, authorship, and/or publication of this article. Elsevier 2022-10-06 /pmc/articles/PMC9561675/ /pubmed/36247925 http://dx.doi.org/10.1016/j.eclinm.2022.101673 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Articles
Fan, K.M.
Rimal, J.
Zhang, P.
Johnson, N.W.
Stark differences in cancer epidemiological data between GLOBOCAN and GBD: Emphasis on oral cancer and wider implications
title Stark differences in cancer epidemiological data between GLOBOCAN and GBD: Emphasis on oral cancer and wider implications
title_full Stark differences in cancer epidemiological data between GLOBOCAN and GBD: Emphasis on oral cancer and wider implications
title_fullStr Stark differences in cancer epidemiological data between GLOBOCAN and GBD: Emphasis on oral cancer and wider implications
title_full_unstemmed Stark differences in cancer epidemiological data between GLOBOCAN and GBD: Emphasis on oral cancer and wider implications
title_short Stark differences in cancer epidemiological data between GLOBOCAN and GBD: Emphasis on oral cancer and wider implications
title_sort stark differences in cancer epidemiological data between globocan and gbd: emphasis on oral cancer and wider implications
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561675/
https://www.ncbi.nlm.nih.gov/pubmed/36247925
http://dx.doi.org/10.1016/j.eclinm.2022.101673
work_keys_str_mv AT fankm starkdifferencesincancerepidemiologicaldatabetweenglobocanandgbdemphasisonoralcancerandwiderimplications
AT rimalj starkdifferencesincancerepidemiologicaldatabetweenglobocanandgbdemphasisonoralcancerandwiderimplications
AT zhangp starkdifferencesincancerepidemiologicaldatabetweenglobocanandgbdemphasisonoralcancerandwiderimplications
AT johnsonnw starkdifferencesincancerepidemiologicaldatabetweenglobocanandgbdemphasisonoralcancerandwiderimplications